Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus

What Was Tested

In this phase 2, phase 3 trial, researchers set out to test Semaglutide.

A total of 226 postpartum individuals with recent GDM will be randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase.

It had two arms (groups): Semaglutide (experimental) and Standard of Care (no intervention).

Participants randomized to the control arm will receive standard postpartum care following a pregnancy complicated by gestational diabetes mellitus (GDM). Standard care will include educational materials addressing postpartum diabetes screening, healthy nutrition, physical activity, weight management, and long-term cardiometabolic risk following GDM. Participants will otherwise receive routine clinical care according to their treating providers and will not receive study-provided semaglutide during the 6-month randomized active phase.

The registry classes the interventions as drug.

Who Took Part

226 planned participants were the target.

It was open to women only aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age greater than or equal to 18. Postpartum state (delivered within 6 weeks). Ability and willingness to provide informed consent.

The full record lists 3 inclusion and 10 exclusion criteria; among the exclusions: a history of acute or chronic pancreatitis; personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma; diagnosis of pre-gestational diabetes (type 1 or 2 diabetes mellitus).

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

The Semaglutide group and the comparison group ran side by side rather than switching.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2027-09-01 with completion listed for 2030-09-01.

It ran at 1 site in United States.

Its stated primary purpose is prevention.

What Was Measured

Primary outcome: Metabolic Syndrome (time frame: 6 months after randomization).

It also tracked 9 secondary outcomes, for example Percent Weight Loss, Body Mass Index, Waist Circumference, Systolic and Diastolic Blood Pressure, Concentration of Fasting Blood Sugar and Concentration of Triglycerides.

What This Means in Plain Language

Put simply, this is a phase 2, phase 3, randomized trial of Semaglutide in 226 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.